Evaluation of methods to detect p53 mutations in ovarian cancer

被引:26
作者
Meinhold-Heerlein, I
Ninci, E
Ikenberg, H
Brandstetter, T
Ihling, C
Schwenk, I
Straub, A
Schmitt, B
Bettendorf, H
Iggo, R
Bauknecht, T
机构
[1] Burnham Inst, Reed Lab, La Jolla, CA 92037 USA
[2] Univ Freiburg, Dept Gynecol & Obstet, D-7800 Freiburg, Germany
[3] Univ Freiburg, Dept Pathol, D-7800 Freiburg, Germany
[4] Swiss Inst Expt Canc Res, Oncogene Grp, Epalinges, Switzerland
[5] Univ Bonn, Dept Gynecol & Obstet, D-5300 Bonn, Germany
关键词
immunohistochemistry; SSCP; FASAY; yeast functional assay; genomic sequencing; comparison of methods; p53; mutations;
D O I
10.1159/000055316
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective: The p53 status is increasingly regarded as a marker predictive of response to particular cancer therapies, but for this approach it is self-evident that the p53 status must be determined correctly. Methods: We have tested ovarian cancers with single-strand conformation polymorphism analysis (SSCP), immunohistochemical staining with DO-1 anti-p53 antibody (IHC), and yeast p53 functional assay (FASAY). Results: These techniques commonly used to detect p53 mutations showed important differences in their sensitivity. Of 53 tumors tested with three indirect techniques, 27 (50%), 33 (62%) and 41 (77%) were positive by SSCP, IHC, and FASAY, respectively. In a subset of 32 tumors strongly suspected of containing mutations, 25 (78%), 26 (81%), 29 (91%) and 30 (94%) were positive by SSCP, immunostaining, DNA sequencing and yeast assay, respectively. Conclusions: Under comparable routine conditions, the FASAY reached the highest sensitivity. Since no single technique detected all mutations, we recommend the use of at least two different techniques in situations where the p53 status will affect patient management. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:176 / 188
页数:13
相关论文
共 59 条
[1]
EXPRESSION OF P21(WAF1/CIP1) IS HETEROGENEOUS AND UNRELATED TO PROLIFERATION INDEX IN HUMAN OVARIAN-CARCINOMA [J].
BARBOULE, N ;
MAZARS, P ;
BALDIN, V ;
VIDAL, S ;
JOZAN, S ;
MARTEL, P ;
VALETTE, A .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (05) :611-615
[2]
BARTEK J, 1990, ONCOGENE, V5, P893
[3]
HEMIZYGOSITY OR HOMOZYGOSITY - A REQUIREMENT FOR SOME BUT NOT OTHER P53 MUTANT PROTEINS TO ACCUMULATE AND EXERT A PATHOGENETIC EFFECT [J].
BHATIA, K ;
GOLDSCHMIDTS, W ;
GUTIERREZ, M ;
GAIDANO, G ;
DALLAFAVERA, R ;
MAGRATH, I .
FASEB JOURNAL, 1993, 7 (10) :951-956
[4]
BLASZYK H, 1995, BIOTECHNIQUES, V18, P256
[5]
BODNER SM, 1992, ONCOGENE, V7, P743
[6]
BUDOWLE B, 1991, AM J HUM GENET, V48, P137
[7]
Casey G, 1996, ONCOGENE, V13, P1971
[8]
Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO
[9]
2-8
[10]
FREQUENT MUTATIONS IN THE P53 TUMOR SUPPRESSOR GENE IN HUMAN LEUKEMIA T-CELL LINES [J].
CHENG, J ;
HAAS, M .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (10) :5502-5509